Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
July 11, 2025
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
January 10, 2023
Related Post
-
-
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
July 11, 2025
-
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
July 10, 2025
-
Agenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
July 7, 2025